
Thermo Fisher Scientific, Inc.
TMOThermo Fisher Scientific, Inc. is a global leader in scientific research and laboratory equipment, providing innovative products and services for life sciences, healthcare, and applied markets. Founded in 2006 through the merger of Thermo Electron and Fisher Scientific, the company specializes in laboratory instrumentation, analytical instruments, reagents, and consumables used in various science and clinical applications. It supports research institutions, pharmaceutical companies, and government agencies with solutions that advance scientific discovery and improve health.
Dividend History
Investors can expect a dividend payout of $0.43 per share, scheduled to be distributed in 9 days on January 15, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 15, 2026 | $0.43 | 2025-12-15 | 2025-12-15 |
| October 15, 2025 | $0.43 | 2025-09-15 | 2025-09-15 |
| July 15, 2025 | $0.43 | 2025-06-13 | 2025-06-13 |
| April 15, 2025 | $0.43 | 2025-03-14 | 2025-03-14 |
| January 15, 2025 | $0.39 | 2024-12-13 | 2024-12-13 |
Dividends Summary
- Thermo Fisher Scientific, Inc. has issued 56 dividend payments over the past 14 years
- The most recent dividend was paid 83 days ago, on October 15, 2025
- The highest dividend payed out to investors during this period was $0.43 per share
- The average dividend paid during this period was $0.23 per share.
Company News
The global GPCRs market is projected to grow from USD 3.92 billion in 2024 to USD 6.04 billion by 2032 at a CAGR of 5.59%, driven by rising drug discovery activities, expanding applications in targeted therapeutics, and increasing prevalence of chronic and neurological disorders. The U.S. market is expected to reach USD 1.66 billion by 2032. Nort...
The article highlights two investment opportunities in the pharmaceutical and medical device sectors that could benefit from AI-driven drug development: Becton Dickinson (BDX) and the BlackRock Health Sciences Fund (BME), both currently undervalued and offering attractive dividend yields.
Thermo Fisher Scientific partnered with GENinCode PLC to manufacture, sell, and distribute the CARDIO inCode-Score genetic heart disease screening test across the U.S., Europe, Middle East, and Africa, aiming to help prevent heart disease through genetic risk assessment.
William Blair analyst Matt Larew initiated coverage of Thermo Fisher Scientific with an outperform rating, highlighting the company's competitive advantages and potential for recovery in the biopharma segment despite current market softness.
The article discusses research reports on Thermo Fisher Scientific, Micron Technology, and KLA. Thermo Fisher is benefiting from new product launches and strong financial performance, while Micron is seeing improved market conditions and rising demand for memory and storage. KLA is performing well due to strong wafer inspection business and AI ad...








